In breast cancer, HER2-directed ADCs, such as trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), have been practice-changing, with T-DXd producing durable responses and activity even in HER2-low disease [62, 63]. The gene discussed is ERBB2; the disease is breast carcinoma.